Anika Therapeutics
Manufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
32 Wiggins Ave, Bedford, Massachusetts, ...Phone Number
(781) 457-9000Website
www.anika.comRevenue
$116.3 MillionStock Symbol
ANIKIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About Anika Therapeutics
Anika Therapeutics is a medical manufacturing company that develops, manufactures, and commercializes therapeutic products based on proprietary hyaluronic acid technology. The company specializes in orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions. Their product portfolio includes orthobiologics for knee osteoarthritis treatment, dermal products for complex wound care, surgical products for post-operative adhesion prevention, ophthalmic products for surgical procedures, and veterinary products for joint dysfunction treatment. Founded in 1983 and headquartered in Bedford, Massachusetts, Anika Therapeutics operates internationally with a focus on innovative medical solutions across multiple healthcare segments.Explore more
Anika Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Anika Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Anika Therapeutics launches new products
Click to see if Anika Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Anika Therapeutics has new funding data
Earning: See what the market has to say on Anika Therapeutics recently announced quarterly report
Anika Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Anika Therapeutics is spiking on competitors!
Check if Anika Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Anika Therapeutics
Recommended Actions
Reach out to Masked Content who joined Anika Therapeutics as Masked Content
Find 2 more new buyers
Compare Similar Companies to Anika Therapeutics
Compare insights from companies similar to Anika Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Anika Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Anika Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Anika Therapeutics.
Anika Therapeutics Tech Stack
A closer look at the technologies used by Anika Therapeutics
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Anika Therapeutics News & Media
Anika Reports First Quarter 2026 Financial Results
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timingAnika to Issue First Quarter 2026 Financial Results on Wednesday, April 29, 2026
BEDFORD, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2026 financial results before the opening of the market on Wednesday, April 29, 2026, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights.Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BEDFORD, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on April 1, 2026, Anika granted restricted stock units (“RSUs”) covering an aggregate of 3,138 shares of common stock to one newly hired non-executive employee. The grant was made pursuant to the Anika Therapeutics, Inc. 2021 Inducement Plan, as amended, wAnika Therapeutics Touts $3B TAM, Cingal & Hyalofast Growth Plans at Canaccord MSK Conference
Anika Therapeutics (NASDAQ:ANIK) CEO Steve Griffin outlined the company’s strategy, product portfolio, and growth priorities during a presentation at the Canaccord Genuity Musculoskeletal Conference, emphasizing a focus on top-line growth, a differentiated hyaluronic acid-based technology platform,
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Anika Therapeutics
Sign Up For FreeTo access detailed company insights
Anika Therapeutics is a medical manufacturing company that develops, manufactures, and commercializes therapeutic products based on proprietary hyaluronic acid technology. The company specializes in orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions. Their product portfolio includes orthobiologics for k... Read More
